Browse by CSHL Author

Paper

Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., Galluzzo, Z. C., Tucker, C., Sheltzer, J. M. (September 2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med, 11 (509). ISSN 1946-6234

Giuliano, C. J., Lin, A., Girish, V., Sheltzer, J. M. (September 2019) Generating Single Cell-Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9. Curr Protoc Mol Biol, 128 (1). e100. ISSN 1934-3639 (Print)1934-3647

Giuliano, C. J., Lin, A., Girish, V., Sheltzer, J. M. (August 2019) Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9. Current Protocols in Molecular Biology, 128 (1). Art number e100. ISSN 19343639 (ISSN)

Shields, M., Maguin, P., Giuliano, C., Dallas, S., Wilkinson, J. E., Egeblad, M. (May 2018) Lysyl oxidases suppress pancreatic cancer progression and inhibit FAK and ERK signaling. Cancer Research, 78 (10 Sup). pp. 76-77. ISSN 0008-5472

Giuliano, C. J., Lin, A., Smith, J. C., Palladino, A. C., Sheltzer, J. M. (February 2018) MELK expression correlates with tumor mitotic activity but is not required for cancer growth. Elife, 7. ISSN 2050-084x

Lin, A., Giuliano, C. J., Sayles, N. M., Sheltzer, J. M. (March 2017) CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife, 6. e24179. ISSN 2050-084x